Sample size for a noninferiority clinical trial with time-to-event data in the presence of competing risks

被引:2
|
作者
Han, Dong [1 ,2 ]
Chen, Zheng [1 ]
Hou, Yawen [3 ]
机构
[1] Southern Med Univ, Sch Publ Hlth, Dept Biostat, Guangdong Prov Key Lab Trop Dis Res, Guangzhou, Guangdong, Peoples R China
[2] Southern Med Univ, Dept Qual Control, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China
[3] Jinan Univ, Dept Stat, Coll Econ, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Competing risks; Noninferiority clinical trials; sample size; sub-distribution hazard ratio; survival data; END-POINTS; MULTISTATE MODELS; FOLLOW-UP; PITFALLS; CANCER;
D O I
10.1080/10543406.2017.1399897
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The analysis and planning methods for competing risks model have been described in the literature in recent decades, and noninferiority clinical trials are helpful in current pharmaceutical practice. Analytical methods for noninferiority clinical trials in the presence of competing risks (NiCTCR) were investigated by Parpia et al., who indicated that the proportional sub-distribution hazard (SDH) model is appropriate in the context of biological studies. However, the analytical methods of the competing risks model differ from those appropriate for analyzing noninferiority clinical trials with a single outcome; thus, a corresponding method for planning such trials is necessary. A sample size formula for NiCTCR based on the proportional SDH model is presented in this paper. The primary endpoint relies on the SDH ratio. A total of 120 simulations and an example based on a randomized controlled trial verified the empirical performance of the presented formula. The results demonstrate that the empirical power of sample size formulas based on the Weibull distribution for noninferiority clinical trials with competing risks can reach the targeted power.
引用
收藏
页码:797 / 807
页数:11
相关论文
共 50 条
  • [31] Statistical power and sample size calculations for time-to-event analysis
    Zurakowski, David
    Staffa, Steven J.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 166 (06): : 1542 - +
  • [32] Sample size adjustment designs with time-to-event outcomes: A caution
    Freidlin, Boris
    Korn, Edward L.
    [J]. CLINICAL TRIALS, 2017, 14 (06) : 597 - 604
  • [33] Comparison of Time-to-Event Data for Clinical Trials
    Nadarajah, Saralees
    [J]. MONTE CARLO METHODS AND APPLICATIONS, 2007, 13 (01): : 21 - 35
  • [34] Quantifying and Comparing Dynamic Predictive Accuracy of Joint Models for Longitudinal Marker and Time-to-Event in Presence of Censoring and Competing Risks
    Blanche, Paul
    Proust-Lima, Cecile
    Loubere, Lucie
    Berr, Claudine
    Dartigues, Jean-Francois
    Jacqmin-Gadda, Helene
    [J]. BIOMETRICS, 2015, 71 (01) : 102 - 113
  • [35] Modeling potential time to event data with competing risks
    Li, Liang
    Hu, Bo
    Kattan, Michael W.
    [J]. LIFETIME DATA ANALYSIS, 2014, 20 (02) : 316 - 334
  • [36] Modeling potential time to event data with competing risks
    Liang Li
    Bo Hu
    Michael W. Kattan
    [J]. Lifetime Data Analysis, 2014, 20 : 316 - 334
  • [37] Bayesian leveraging of historical control data for a clinical trial with time-to-event endpoint
    Roychoudhury, Satrajit
    Neuenschwander, Beat
    [J]. STATISTICS IN MEDICINE, 2020, 39 (07) : 984 - 995
  • [38] Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data
    Jinks, Rachel C.
    Royston, Patrick
    Parmar, Mahesh K. B.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2015, 15
  • [39] Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size
    Xu, Rengyi
    Mehrotra, Devan V.
    Shaw, Pamela A.
    [J]. PHARMACEUTICAL STATISTICS, 2019, 18 (03) : 366 - 376
  • [40] Meta-analysis of clinical trials with competing time-to-event endpoints
    Meddis, Alessandra
    Latouche, Aurelien
    Zhou, Bingqing
    Michiels, Stefan
    Fine, Jason
    [J]. BIOMETRICAL JOURNAL, 2020, 62 (03) : 712 - 723